SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2026)
SAB Biotherapeutics (SABS) reported Retained Earnings of -$129.8 million for Q1 2026, little changed on a YoY basis from -$130.2 million in Q1 2025, and down 69694.12% quarter-over-quarter from $186510.0 in Q4 2025.
SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Retained Earnings for 7 years, with the latest figure at -$129.8 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings changed 0.31% year-over-year to -$129.8 million; the trailing twelve-month figure through Mar 2026 stood at -$129.8 million (changed 0.31% YoY), and the FY2025 full-year result was $186510.0, up 237.74% from the prior year.
- Retained Earnings for Q1 2026 stood at -$129.8 million, down from $186510.0 in the prior quarter.
- The five-year high for Retained Earnings was $186510.0 in Q4 2025, with the low at -$139.5 million in Q2 2025.
- Historically, Retained Earnings has averaged -$66.8 million across 5 years, with a median of -$62.1 million in 2023.
- Annual changes were most pronounced in 2024 — Retained Earnings tumbled 612.53% — and 2025, when it surged 237.74%.
- SAB Biotherapeutics' Retained Earnings stood at -$47.9 million in 2022, then surged by 100.06% to $26420.0 in 2023, then plunged by 612.53% to -$135410.0 in 2024, then surged by 237.74% to $186510.0 in 2025, then slumped by 69694.12% to -$129.8 million in 2026.
- The last three Retained Earnings figures came in at -$129.8 million (Q1 2026), $186510.0 (Q4 2025), and -$94.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -129.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.80 Mn |
| Dec 31, 2025 | 186,510.00 |
| Sep 30, 2025 | -94.03 Mn |
| Jun 30, 2025 | -139.50 Mn |
| Mar 31, 2025 | -129.40 Mn |
| Dec 31, 2024 | -135,410.00 |
| Sep 30, 2024 | -112.77 Mn |
| Jun 30, 2024 | -102.40 Mn |
| Mar 31, 2024 | -95.09 Mn |
| Dec 31, 2023 | 26,420.00 |
| Sep 30, 2023 | -67.21 Mn |
| Jun 30, 2023 | -62.10 Mn |
| Mar 31, 2023 | -55.22 Mn |
| Dec 31, 2022 | -47.87 Mn |
| Sep 30, 2022 | -40.00 Mn |
| Jun 30, 2022 | -32.92 Mn |
| Mar 31, 2022 | -28.14 Mn |
| Dec 31, 2021 | -29.13 Mn |
| Sep 30, 2021 | -9.29 Mn |
| Jun 30, 2021 | -8.96 Mn |